07:00 , Oct 6, 2014 |  BioCentury  |  Finance

Winner takes Alios

Antiviral developer Alios BioPharma Inc. raised strategic investments from three pharmas, but they all lost out to Johnson & Johnson (NYSE:JNJ). With a $1.7 billion bid on Sept. 30, J&J netted a candidate in Phase...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Company News

Alios, J&J deal

Johnson & Johnson is acquiring Alios for about $1.8 billion in cash. The pharma receives Alios' antiviral assets, including AL-8176 to treat respiratory syncytial virus (RSV) infection. In July, the oral nucleoside analog met...
03:26 , Oct 1, 2014 |  BC Extra  |  Top Story

J&J buying Alios for $1.75B

Johnson & Johnson (NYSE:JNJ) is acquiring Alios BioPharma Inc. (South San Francisco, Calif.) for $1.75 billion in cash. The pharma receives Alios' antiviral assets, including AL-8176 to treat respiratory syncytial virus (RSV). In July, the...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

AL-8176: Phase II data

A double-blind, U.K. Phase II trial in 62 healthy volunteers infected intranasally with RSV showed that twice-daily oral AL-8176 for 5 days met the primary endpoint of reducing viral load vs. placebo (p<0.0002). Specifically, all...
01:26 , Apr 8, 2014 |  BC Extra  |  Financial News

Alios raises $41 million in series B

Viral disease play Alios BioPharma Inc. (South San Francisco, Calif.) raised $41 million in a series B round led by a new undisclosed investor. All of the company's existing investors -- Novo Ventures; SR One;...
08:00 , Jan 27, 2014 |  BC Week In Review  |  Clinical News

AL-8176: Phase IIa started

Alios began the double-blind, placebo-controlled Phase IIa AL-8176-502 trial to evaluate multiple doses of oral AL-8176 for 5 days in about 66 healthy volunteers who will be inoculated with RSV. Alios BioPharma Inc., South San...
08:00 , Nov 14, 2013 |  BC Innovations  |  Targets & Mechanisms

RSVing for site zero

Despite decades of research, respiratory syncytial virus (RSV) remains a highly prevalent childhood pathogen without an approved vaccine.1 There is a marketed prophylactic-Synagis palivizumab-to prevent severe disease caused by RSV in at-risk infants, but the...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Clinical News

ALS-8176: Phase I started

Alios began a double-blind, placebo-controlled Phase I trial to evaluate single and multiple ascending-doses of oral ALS-8176 in up to 90 healthy volunteers. Alios BioPharma Inc., South San Francisco, Calif.   Product: ALS-8176   Business: Infectious...